Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia

References

• Kim J, Kim Y. A time-cost augmented economic evaluation of oral deferasirox versus infusional deferoxamine [corrected] for patients with iron overload in South Korea. Value Health 2009;12(3 Suppl):S78-81
   PubMed Web of Science ®Google Scholar
• Payne KA, Rofail D, Baladi J-F, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Adv Ther 2008;25:725-42
   PubMed Web of Science ®Google Scholar
• Vichinsky EP, Ohene-Frempong K, Thein SL, et al. Transfusion and chelation practices in sickle cell disease: a regional perspective. Pediatr Hematol Oncol 2011;28:124-33
   PubMed Web of Science ®Google Scholar
• Blinder MA, Vekeman F, Sasane M, et al. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer 2013;60:828-35
   PubMed Web of Science ®Google Scholar
• Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008;83:398-402
   PubMed Web of Science ®Google Scholar
• Galanello R. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Ther Clin Risk Manag 2007;3:795-805
   PubMedGoogle Scholar
• Trachtenberg FL, Gerstenberger E, Xu Y, et al. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia. Qual Life Res 2014;23:2277-88
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Bernaudin F, Forni GL, et al. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011;154:387-97
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-62
   PubMed Web of Science ®Google Scholar
• Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006;91:873-80
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-8
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
   PubMed Web of Science ®Google Scholar
• Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy 2006;26:1157-64
   PubMed Web of Science ®Google Scholar
• Porter JB. Practical management of iron overload. Br J Haematol 2001;115:239-52
   PubMed Web of Science ®Google Scholar
• Raphael JL, Bernhardt MB, Mahoney DH, et al. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer 2009;52:616-20
   PubMed Web of Science ®Google Scholar
• Jordan LB, Vekeman F, Sengupta A, et al. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease. J Clin Pharm Ther 2012;37:173-81
   PubMed Web of Science ®Google Scholar
• Jensen GA, Li Y. Long-run health effects of cost-related non-adherence to prescribed medications among adults in late midlife. J Pharm Heal Serv Res 2012;3:85-93
   Google Scholar
• Cutler DM, Everett W. Thinking outside the pillbox–medication adherence as a priority for health care reform. N Engl J Med 2010;362:1553-5
   PubMed Web of Science ®Google Scholar
• Stefanacci RG, Guerin SP. Why medication adherence matters to patients, payers, providers. Managed care magazine online. Manag Care 2013;22(1); p.37-39
   PubMedGoogle Scholar
• Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000;110:971-7
   PubMed Web of Science ®Google Scholar
• Bosi G, Crepaz R, Gamberini MR, et al. Left ventricular remodelling, and systolic and diastolic function in young adults with beta thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data. Heart 2003;89:762-6
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-93
   PubMed Web of Science ®Google Scholar
• Renfroe JL, Forbes P, Braunstein J, Neufeld EJ. Relationship of transfusion and iron-related complications to cost of care in thalassemia. ASH Annu Meet Abstr 2005;106:2240
   Google Scholar
• Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007;47:1919-29
   PubMed Web of Science ®Google Scholar
• American Pharmacists Association. "Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality." Journal of the American Pharmacists Association: JAPhA 54.3 (2013): 228-240.
   Google Scholar
• Aitken, M., and S. Valkova. "Avoidable costs in US Healthcare." IMS Institute for Healthcare Informatics, Parsippany, NJ (2013).
   Google Scholar
• Blinder MA, Duh MS, Sasane M, et al. Age-related emergency department reliance in patients with sickle cell disease. J Emerg Med 2015;49:513-22.e1
   PubMed Web of Science ®Google Scholar
• Desrosiers M-P, Payne KA, Baladi J-F. Estimating the total cost of infused iron chelation therapy. ASH Annu Meet Abstr 2005;106:5576
   Google Scholar
• Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011;364:146-56
   PubMed Web of Science ®Google Scholar
• Weissman L, Treadwell MVE. Evaluation of home desferal care in transfusion dependent children with thalassemia and sickle cell disease. J Pediatri Hematol Oncology 1996;18(4):454-5
   Google Scholar
• Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. Eur J Clin Pharmacol 2001;56:915-22
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ward A, Green TC, et al. Impact of thalassemia major on patients and their families. Acta Haematol 2002;107:150-7
   PubMed Web of Science ®Google Scholar
• Ward A, Caro JJ, Green TC, et al. An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use. BMC Clin Pharmacol 2002;2:3
   PubMedGoogle Scholar
• Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major in North America. Blood 2004;104:34-9
   PubMed Web of Science ®Google Scholar